Immuron

Analyst Reports

Corporate Governance

Corporate Directory

Corporate

Capital Structure & Register

Annual Reports

Investor Presentations

NASDAQ

Investors

Company Media

Announcements

The Digest

Why Immuron?

Home

Plus Jakarta Sans

Click here to read full article

Immuron’s board has green‑lit cGMP manufacturing of IMM‑529, its next‑generation therapeutic targeting Clostridioides difficile infection (CDI), and authorized the company to submit a pre‑IND package to the FDA, advancing the candidate toward formal clinical development. IMM‑529’s mechanism is designed to simultaneously target three critical aspects of CDI—spores, vegetative cells, and Toxin B—and has drawn favorable feedback from experts and analysts, with Lumanity estimating a potential U.S. annual revenue of around USD $92 million under base‑case scenarios. This move significantly accelerates Immuron’s pipeline progression in the recurrent CDI space.

Proactive: Immuron to go ahead with IMM-529 cGMP manufacturing and proceed with FDA pre-IND submission